Catheter Precision announced the publication of a study showing its LockeT device had significantly fewer complications and a 0% failure rate compared to Abbott's Perclose device for vascular closure. This positive clinical data could enhance LockeT's market adoption and competitive position against a major incumbent.
Catheter Precision (VTAK) published results from a comparative study in The Journal of Interventional Cardiology, demonstrating its LockeT device had a significantly lower complication rate (1.2% vs. 9.3%) and a 0% device failure rate compared to Abbott's (ABT) Perclose device. This is a direct head-to-head comparison against a market leader, highlighting a potential competitive advantage for LockeT. For VTAK, this positive clinical validation could drive increased adoption and market share, representing a significant long-term opportunity. For ABT, while Perclose is just one of many products, this data could pose a competitive threat in the large bore venous access market, potentially impacting future sales if LockeT gains traction. Traders should watch for VTAK's ability to leverage these results into sales growth and ABT's response to this competitive pressure.